Literature DB >> 32557246

In vitro antifungal susceptibility of Sporothrix globosa isolates from Jilin Province, northeastern China: comparison of yeast and mycelial phases.

Yang Song1, Shanshan Li1, Ying Shi1, Lipei Zhao2, Yu Cui3, Lei Yao1, Yu Zhen1, Ruili Chen1, Yan Cui4.   

Abstract

The dimorphic fungus Sporothrix globosa is the predominant etiologic agent causing sporotrichosis in China, particularly in the northeast. It has been demonstrated that the incubation temperature and growth phase can influence in vitro antifungal susceptibility profiles of S. schenckii sensu stricto and S. brasiliensis (sibling species of S. globosa). Few studies have reported on the antifungal susceptibility of S. globosa, especially using large numbers of isolates. In this study, we assessed the susceptibility of 80 isolates of S. globosa originating from Jilin Province, northeastern China, to six antifungal agents (itraconazole, terbinafine, voriconazole, posaconazole, fluconazole, and amphotericin B), at varying incubation temperatures and in different fungal growth phases. The isolates were most sensitive to terbinafine (geometric mean [GM] of the minimum inhibitory concentration [MIC]: 0.0356 μg/ml for the mycelial phase at 30 °C, 0.0332 μg/ml for the mycelial phase at 35 °C, and 0.031 μg/ml for the yeast phase, respectively), followed by posaconazole (GM of the MIC: 4.2501 μg/ml for the mycelial phase at 30 °C, 1.4142 μg/ml for the mycelial phase at 35 °C, and 0.7195 μg/ml for the yeast phase, respectively) and itraconazole (GM of the MIC: 6.8448 μg/ml for the mycelial phase at 30 °C, 3.1383 μg/ml for the mycelial phase at 35 °C, and 1.0263 μg/ml for the yeast phase, respectively). The isolates were relatively resistant to fluconazole (GM of the MIC: 76.7716 μg/ml for the mycelial phase at 30 °C, 66.2570 μg/ml for the mycelial phase at 35 °C, and 24.4625 μg/ml for the yeast phase, respectively) and voriconazole (GM of the MIC: 26.2183 μg/ml for the mycelial phase at 30 °C, 13.6895 μg/ml for the mycelial phase at 35 °C, and 1.3899 μg/ml for the yeast phase, respectively). For all the tested azole drugs, the MICs at 30 °C were significantly higher than those at 35 °C (P < 0.001); for all agents except terbinafine, the MICs of S. globosa in the yeast phase were significantly lower than those of the strains in the mycelial phase (P < 0.001). These results show that the sensitivities of S. globosa to antifungal compounds are dependent on incubation temperature and growth phase. To the best of our knowledge, this is the largest study of antifungal susceptibility of S. globosa isolates reported to date. To establish epidemiological cutoff values for S. globosa, further antifungal susceptibility testing studies by independent laboratories located in different regions and using uniform conditions are required.

Entities:  

Keywords:  Antifungal susceptibility; Growth phase; Incubation temperature; Sporothrix globosa; Sporothrix schenckii

Year:  2020        PMID: 32557246      PMCID: PMC7966605          DOI: 10.1007/s42770-020-00316-y

Source DB:  PubMed          Journal:  Braz J Microbiol        ISSN: 1517-8382            Impact factor:   2.476


  32 in total

Review 1.  Inhibition and induction of human cytochrome P450 (CYP) enzymes.

Authors:  O Pelkonen; J Mäenpää; P Taavitsainen; A Rautio; H Raunio
Journal:  Xenobiotica       Date:  1998-12       Impact factor: 1.908

2.  Multicenter, International Study of MIC/MEC Distributions for Definition of Epidemiological Cutoff Values for Sporothrix Species Identified by Molecular Methods.

Authors:  A Espinel-Ingroff; D P B Abreu; R Almeida-Paes; R S N Brilhante; A Chakrabarti; A Chowdhary; F Hagen; S Córdoba; G M Gonzalez; N P Govender; J Guarro; E M Johnson; S E Kidd; S A Pereira; A M Rodrigues; S Rozental; M W Szeszs; R Ballesté Alaniz; A Bonifaz; L X Bonfietti; L P Borba-Santos; J Capilla; A L Colombo; M Dolande; M G Isla; M S C Melhem; A C Mesa-Arango; M M E Oliveira; M M Panizo; Z Pires de Camargo; R M Zancope-Oliveira; J F Meis; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

3.  In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

4.  In vitro antifungal susceptibilities of five species of sporothrix.

Authors:  Rita Marimon; Carolina Serena; Josepa Gené; Josep Cano; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2007-11-26       Impact factor: 5.191

5.  Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America.

Authors:  Carol A Kauffman; Beatriz Bustamante; Stanley W Chapman; Peter G Pappas
Journal:  Clin Infect Dis       Date:  2007-10-08       Impact factor: 9.079

6.  MICs and minimum fungicidal concentrations of amphotericin B, itraconazole, posaconazole and terbinafine in Sporothrix schenckii.

Authors:  Carolina Pereira Silveira; Josep M Torres-Rodríguez; Eidi Alvarado-Ramírez; Francisca Murciano-Gonzalo; Maribel Dolande; Mercedes Panizo; Vera Reviakina
Journal:  J Med Microbiol       Date:  2009-08-13       Impact factor: 2.472

7.  Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest.

Authors:  Rita Marimon; Josep Cano; Josepa Gené; Deanna A Sutton; Masako Kawasaki; Josep Guarro
Journal:  J Clin Microbiol       Date:  2007-08-08       Impact factor: 5.948

8.  The difficult management of disseminated Sporothrix brasiliensis in a patient with advanced AIDS.

Authors:  Ariane Gomes Paixão; Maria Clara Gutierrez Galhardo; Rodrigo Almeida-Paes; Estevão Portela Nunes; Marcelo Luiz Carvalho Gonçalves; Gisele Larias Chequer; Cristiane da Cruz Lamas
Journal:  AIDS Res Ther       Date:  2015-05-07       Impact factor: 2.250

9.  Sporotrichosis in the Highlands of Madagascar, 2013-20171.

Authors:  Tahinamandranto Rasamoelina; Danièle Maubon; Onivola Raharolahy; Harinjara Razanakoto; Njary Rakotozandrindrainy; Fetra Angelot Rakotomalala; Sébastien Bailly; Fandresena Sendrasoa; Irina Ranaivo; Malalaniaina Andrianarison; Benja Rakotonirina; Abel Andriantsimahavandy; Fahafahantsoa Rapelanoro Rabenja; Mala Rakoto Andrianarivelo; Lala Soavina Ramarozatovo; Muriel Cornet
Journal:  Emerg Infect Dis       Date:  2019-10       Impact factor: 6.883

10.  Genetic variation of Sporothrix globosa isolates from diverse geographic and clinical origins in China.

Authors:  Lipei Zhao; Yan Cui; Yu Zhen; Lei Yao; Ying Shi; Yang Song; Ruili Chen; Shanshan Li
Journal:  Emerg Microbes Infect       Date:  2017-10-11       Impact factor: 7.163

View more
  2 in total

1.  Special issue on sporotrichosis: challenges to deal with the new emerging pathogenic species.

Authors:  Leila M Lopes-Bezerra; Sandro Rogério de Almeida
Journal:  Braz J Microbiol       Date:  2021-02-18       Impact factor: 2.476

Review 2.  Biological and Clinical Attributes of Sporothrix globosa, a Causative Agent of Sporotrichosis.

Authors:  Laura C García-Carnero; Héctor M Mora-Montes; Nallely Nava-Pérez; Lisset G Neri-García; Oscar E Romero-González; Joshua A Terrones-Cruz
Journal:  Infect Drug Resist       Date:  2022-04-22       Impact factor: 4.177

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.